Olanzapine Versus An Active Comparator in the Treatment of Schizophrenia

The purpose of this study is to determine how Olanzapine compares to an active comparator in the treatment of schizophrenia

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Schizophrenia Mental Disorders Schizophrenia Spectrum and Other Psychotic Disorders

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

La Plata, Buenos Aires, Argentina

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion:

You must be between the ages of 18 and 75. If you have reached your 76th birthday, you will not be able to participate
You must have been diagnosed with schizophrenia
You must be able to visit the doctor's office as scheduled for the next 7 months

Exclusion:

You have a serious medical illness, such as heart, liver, or kidney disease (Note: If you are uncertain about a particular condition, discuss it with your doctor.)
You are either pregnant or breastfeeding

Treatment and study plan

Olanzapine

Drug

Sponsors and collaborators

Lead sponsor

Eli Lilly and Company

Industry

Registry information

Important dates

Study start: 2001
Study completion: 2002
First posted: May 8, 2002
Registry last updated: Jul 19, 2006

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed